Bone Biologics Prices $2 Million Public Offering

Bone Biologics announced the pricing of its public offering. Total gross proceeds are expected to be approximately $2.0 million. Net proceeds will fund clinical trials, maintain and extend its patent portfolio, and support working capital and other general corporate purposes.

NELL-1 is a recombinant human protein that Bone Biologics licensed...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us